AnaptysBio (NASDAQ:ANAB) Price Target Raised to $45.00

AnaptysBio (NASDAQ:ANAB) had its target price upped by Wedbush from $40.00 to $45.00 in a research report sent to investors on Thursday,Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock. Wedbush also issued estimates for AnaptysBio’s Q4 2026 earnings at ($0.84) EPS.

Several other research analysts also recently weighed in on ANAB. Guggenheim reiterated a “buy” rating and issued a $90.00 price target (up from $54.00) on shares of AnaptysBio in a report on Wednesday, May 28th. HC Wainwright upgraded AnaptysBio from a “neutral” rating to a “buy” rating and boosted their price target for the company from $22.00 to $38.00 in a report on Wednesday, June 4th. Finally, JPMorgan Chase & Co. boosted their price target on AnaptysBio from $42.00 to $80.00 and gave the company an “overweight” rating in a report on Thursday, July 24th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, AnaptysBio presently has an average rating of “Moderate Buy” and an average target price of $47.75.

AnaptysBio Stock Performance

ANAB stock opened at $21.03 on Thursday. AnaptysBio has a 1 year low of $12.21 and a 1 year high of $41.31. The stock’s 50 day moving average price is $24.19 and its 200 day moving average price is $20.47. The firm has a market cap of $588.78 million, a P/E ratio of -4.69 and a beta of -0.20.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.50) by $0.16. AnaptysBio had a negative return on equity of 366.98% and a negative net margin of 107.66%. The firm had revenue of $22.26 million for the quarter, compared to analyst estimates of $11.55 million. On average, research analysts predict that AnaptysBio will post -6.08 earnings per share for the current year.

Insider Activity at AnaptysBio

In other news, Director Hollings Renton sold 20,925 shares of the company’s stock in a transaction on Wednesday, July 2nd. The stock was sold at an average price of $23.57, for a total transaction of $493,202.25. Following the completion of the sale, the director directly owned 4,965 shares in the company, valued at $117,025.05. This represents a 80.82% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 33.50% of the stock is currently owned by insiders.

Institutional Trading of AnaptysBio

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Intech Investment Management LLC acquired a new stake in shares of AnaptysBio during the 2nd quarter worth $240,000. Creative Planning increased its holdings in shares of AnaptysBio by 26.9% during the 2nd quarter. Creative Planning now owns 16,854 shares of the biotechnology company’s stock worth $374,000 after buying an additional 3,571 shares during the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of AnaptysBio during the 2nd quarter worth $334,000. Savant Capital LLC acquired a new stake in shares of AnaptysBio during the 2nd quarter worth $241,000. Finally, Corton Capital Inc. increased its holdings in shares of AnaptysBio by 12.2% during the 2nd quarter. Corton Capital Inc. now owns 12,004 shares of the biotechnology company’s stock worth $266,000 after buying an additional 1,305 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.